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bstract
The efficacy and tolerability of intravenous (i.v.) iron in managing cancer-related anemia and iron deficiency has been clinically evaluated
nd reviewed recently. However, long-term data in cancer patients are not available; yet, long-term i.v. iron treatment in hemodialysis patients is
ot associated with increased cancer risk. This review summarizes epidemiological and nonclinical data on the role of iron in carcinogenesis.
n humans, epidemiological data suggest correlations between certain cancers and increased iron exposure or iron overload. Nonclinical
odels that investigated whether iron can enhance carcinogenesis provide only limited evidence relevant for cancer patients since they were
ypically based on high iron doses as well as injection routes and iron formulations which are not used in the clinical setting. Nevertheless, in
he absence of long-term outcome data from prospectively defined trials in i.v. iron-treated cancer patients, iron supplementation should be
imited to periods of concomitant anti-tumor treatment.
 2013 The Authors. Published by Elsevier Ireland Ltd. 
onclini
t
n
i
t
m
i
p
t
O
e
m
t
t
l
s
h
a
t
s
d
i
i
i
i
2
2
Open access under CC BY-NC-ND license. eywords: Iron deficiency; Anemia; Carcinogenesis; Tumor progression; N
.  Introduction
Iron-containing proteins participate in many essential
iological processes such as oxygen transport, cellular res-
iration and redox reactions. However, ferrous iron (Fe2+)
an catalyze the production of hydroxyl radicals (•OH) [1]
hich are stronger oxidants than the antimicrobial superox-
de radicals (O2•−), and therefore can exert oxidative damage
o nearby lipids, carbohydrates, proteins or DNA. Since iron
s not actively secreted from the body, systemic iron levels
re regulated by the liver-derived peptide hepcidin, whereas
ellular iron levels are controlled by iron-regulatory proteins
IRPs) that bind to iron-response elements (IREs) in the mes-
enger RNA of iron-related genes (Fig. 1) [2,3]. These highly
onserved mechanisms of iron sequestration also provide
rotection against infectious diseases by depriving invad-
ng pathogens of this essential nutrient [4,5]. However, these
echanisms are also activated by inflammatory processes
ssociated with chronic diseases such as cancer.
Interleukin (IL)-6 and IL-1 are the main inflammatory
ffectors that increase the expression of hepcidin [2], which
n turn deactivates ferroportin, the iron export protein on the
urface of enterocytes, hepatocytes and macrophages [6,7].
he reduced absorption and release of iron leads to an imbal-
nce between iron requirements for erythropoiesis in the bone
arrow and the iron supply from macrophages. This func-
ional iron deficiency (FID) is believed to be one of the major
auses of the anemia of chronic disease (ACD). Conversely,
ow hepcidin activity results in increased dietary absorption
nd mobilization of iron from cellular stores, which can result
n iron overload.In cancer patients, anemia is associated with shorter
urvival time [8], and symptoms of iron deficiency and
nemia (e.g. weakness and fatigue) affect patients’ quality
f life [9,10]. Intravenous (i.v.) iron in conjunction with
rythropoiesis-stimulating agents (ESAs) has been shown
h
p
a
bcal; Intravenous iron; Parenteral iron
o improve hemoglobin status and reduce blood transfusion
eeds in anemic cancer patients [9,11–17]. In contrast, oral
ron has very limited efficacy in this patient population, and
herefore, treatment guidelines recommend i.v. iron supple-
entation [18,19].
Although i.v. iron preparations passed genotoxicity test-
ng (e.g. Ames) as part of the development and approval
rocess, an open question remains whether iron supplemen-
ation of cancer patients might influence tumor progression.
ne preliminary study with long-term follow-up showed no
ffect of i.v. iron on 3-year progression-free survival in ane-
ic patients with lymphoid malignancies [20,21]. However,
here are insufficient data from prospectively defined studies
o address this question. Several prior reviews have out-
ined mechanisms how elevated iron levels may influence
ignaling pathways and tumor progression or, vice versa,
ow signaling through certain pathways may contribute to
ltered iron metabolism in cancer patients [1,22–24]. In order
o facilitate informed decisions on the clinical use of i.v. iron
upplementation, the review presented here evaluates how the
esigns and results of published epidemiological and nonclin-
cal studies compare to the clinical use of i.v. iron, which is
ntended to provide sufficient iron availability and normal-
zation of hemoglobin levels in patients with cancer-related
ron deficiency or anemia.
. Clinical  data
.1. Hereditary  hemochromatosis
The most common cause of iron overload is hereditary
emochromatosis (HH), a genetic condition with inappro-
riately low hepcidin levels or activity. This results in
ccumulation of iron in the liver and other organs and can
e diagnosed by transferrin saturation >45% and elevated
Y. Beguin et al. / Critical Reviews in Oncology/Hematology 89 (2014) 1–15 3
Fig. 1. Cellular iron metabolism – iron uptake and efflux in normal and cancer cells. (A) Circulating iron is generally bound to transferrin (TF). TF-bound iron
binds to transferrin receptor (TFR) on the plasma membrane of most cells, and the TF-[Fe3+]2-TFR complex is internalized by endocytosis. In the endosome,
Fe3+ is reduced to Fe2+ and transported into the cytosolic labile iron pool (LIP) that harbors the metabolically active forms of cellular iron. From the LIP, iron
is delivered to intracellular compartments such as the nucleus and mitochondria (for metabolic utilization), to cytoplasmic ferritin (for storage in a bioavailable,
non-toxic form) or exported from the cell by ferroportin, an iron efflux pump. (B) On the cellular level, iron metabolism is controlled by iron-regulatory proteins
(IRP). Under conditions of low intracellular iron levels, iron-regulatory proteins (IRP) bind to iron-response elements (IRE) present in the untranslated regions
of mRNAs encoding ferritin subunits, ferroportin, isoforms of divalent metal transporter 1 (DMT1) and TFR. Binding stabilizes the mRNAs that encode TFR
and DMT1, and represses the translation of ferritin and ferroportin. The net result is an increase in iron uptake and a decrease in iron storage and efflux. (C)
Systemic iron homeostasis is largely controlled by hepcidin, a key iron regulatory hormone. Hepcidin downregulates ferroportin and thereby inhibits iron efflux
from duodenal enterocytes, macrophages, and hepatocytes into the circulation. (D) High amounts of systemic iron may lead to saturation of TF and subsequent
formation of non-transferrin bound iron (NTBI). NTBI is taken up non-selectively by tissues and can lead to the formation of reactive oxygen species (ROS),
causing oxidative stress and ultimately cell damage. (E) In cancer cells, genes encoding proteins that increase intracellular iron (TFR, DMT1, hepcidin) are
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[29,30]. Several studies and a large meta-analysis investi-enerally upregulated, whilst those decreasing iron levels (ferroportin) are 
RP, iron regulatory protein; LIP, labile iron pool; NTBI, non-transferrin bo
erum ferritin levels whereupon a ferritin >1000 together
ith elevated aminotransferase levels may be indicative
f a risk of cirrhosis [25]. Typical complications associ-
ted with HH are liver cirrhosis, diabetes, hypogonadism,
nd cardiomyopathy [26]. Complications are avoidable if
erum iron levels are successfully managed by phlebotomy
efore cirrhosis develops [27]. Individuals with HH were
riginally thought to have an up to 200-fold higher risk
f hepatocellular carcinoma (HCC), but more conservative
stimates suggest that a 20-fold increase may be more real-
stic [28]. Since HCC occurs almost exclusively in HH
atients who have developed cirrhosis, there is limited
g
w
rgulated. DMT1, divalent metal transporter 1; IRE, iron-response element;
; ROS, reactive oxygen species; TF, transferrin; TFR, transferrin receptor.
vidence of a direct role for excess iron in carcinogenesis;
nstead, cirrhosis may provide the link for progression to
CC.
Increased risk of developing HCC also exists with a
isorder called African iron overload (AIO), which most
robably arises through interaction between environmental
actors (e.g. consumption of iron-rich beverages brewed in
on-galvanized steel drums) and potential genetic factorsating the risk of non-hepatic cancers in patients with HH or
ith HH-predisposing genotypes have provided conflicting
esults [27,31–36] considerable.
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Table 1
Epidemiological studies investigating iron status and risk of cancer.
Study design, population, study name, follow-up (FU) Key outcomes Ref.
Prospective cohort study, adults, AMORIS, 10.6 y FU High TIBC (i.e. low TSAT) associated with increased cancer risk [58]
Retrospective cohort, adults Iron overload as well as iron deficiency affect PFS and OS [146]
Prospective cohort, adults, NHANES I, 10–13 y FU Higher TSAT in men who developed cancer, no effect of dietary iron [54]
Prospective cohort, adults, NHANES I, 13–17 y FU Higher TSAT in men and women who developed cancer [55]
Prospective cohort, males, 12 y FU No relationship between dietary iron intake and bladder cancer [51]
Prospective cohort, adults, NHANES II, 12–16 y FU High serum iron or TSAT associated with increased risk of cancer death [57]
Prospective cohort, adults, NHANES I, 18–21 y FU High TSAT and high iron intake associated with high cancer risk [53]
Prospective cohort, adults, Framingham Offspring Study, 14 y FU Elevated serum iron associated with development of cancer [52]
Prospective cohort, adults, NHANES I, 18–21 y FU Elevated serum iron and cholesterol in subjects who developed cancer [56]
Prospective cohort, adults, SU.VI.MAX, 7.5 y FU High ferritin in women who developed cancer, no effect of dietary iron [59]
Prospective cohort, women, CNBSS, 16.4 y FU No association of iron or heme iron intake with breast cancer risk [47]
Prospective controlled trial, chronic hepatitis C, up to 12 y FU Phlebotomy and low iron diet lowered the risk of HCC [62]
Retrospective nested case-control study, blood donors, 3–12 y FU Repeated blood donation had no effect on cancer risk [60]
Prospective cohort, endometrial cancer cases, CNBSS, 16.4 y FU No effect of meat or dietary iron intake [50]
Retrospective nested case-control study, Barrett’s esophagus No difference in TSAT and serum ferritin vs. matched controls [31]
Randomized controlled single-blinded trial, PAD, 4.5 y mean FU Lower risk of new visceral malignancy in the phlebotomy arm [61]
Retrospective, population-based case-control study High daily intake of animal-derived iron associated with breast cancer [49]
Prospective nested case-control study, breast cancer, 9–11 y FU No effect of either dietary iron intake or increased serum ferritin levels [48]
Retrospective nested case-control study, blood donors Depending on tumor type, Hb decline started 1–3 y before diagnosis [156]
AMORIS, Apolipoprotein Mortality Risk Study; CNBSS, Canadian National Breast Screening Study; FU, follow-up; Hb, hemoglobin; HCC, hepatocellular
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developing cancer only in women with elevated serum ferritinarcinoma; NHANES, National Health and Nutrition Examination Survey; O
U.VI.MAX, Supplementation en Vitamins et Mineraux Antioxydants; TIB
.2.  Epidemiology  of  iron  intake,  iron  status  and  cancer
isk
Many epidemiological studies have searched more
roadly for a link between cancer and environmental expo-
ure to iron, dietary iron intake, or iron status (relevant studies
ince a 1998 review [22] are summarized in Table 1). Studies
xploring excessive environmental exposure to iron are often
imited by poor characterization of the environmental factors
nd causal relations to effects other than the chemical proper-
ies of iron [37]. Population studies relating to gastrointestinal
GI) cancers have been reviewed recently in detail elsewhere
38,39].
Although most population studies support an association
etween colorectal cancer (CRC) risk and iron exposure
40–42], there are others that do not [41,43,44]. In fact,
ron deficiency might also be associated with an increased
isk of GI malignancies [39], particularly in Helicobacter
ylori-infected patients [45], and iron may modulate cancer
isk differently in different regions of the GI tract. A case-
ontrolled study suggested that increased CRC risk is related
o luminal exposure to excessive iron (combined with a high
at diet) rather than increased iron stores (based on serum
erritin levels) [44]. In addition to geographic region-specific
ifferences, other factors such as different dietary habits, iron
tatus assessment or iron intake/supplementation complicate
nterpretation or comparison of epidemiological studies.
Where correlations between high red meat consumption
nd CRC risk have been identified [40,42], it is difficult to dis-
inguish whether the heme iron or saturated fat constituents
ave contributed to the associated risk [38]. Moreover,
onsidering the contribution of iron alone, in one study fecal
evels of carcinogenic N-nitrosated products were higher in
[
i
sll survival; PAD, peripheral arterial disease; PFS, progression-free survival;
l iron binding capacity; TSAT, transferrin saturation.
ealthy volunteers fed a diet high in red meat or the equivalent
mount of heme, than in those whose diet was supplemented
ith ferrous salts [46].
Compared to the well-explored epidemiology of CRC, few
opulation studies have focused on the role of iron in other
ancers. Two studies on breast cancer did not demonstrate a
trong link between iron status and cancer risk [47,48]. In a
hinese cohort study, women with elevated serum ferritin
evels had more fibrocystic changes, but these were non-
roliferative, and no link between iron and breast cancer was
bserved [48]. High intake of animal-derived iron (mainly
eme) and fat were both associated with an increased risk of
rimary breast cancer [49]. Studies investigating endometrial
ancer [50], bladder cancer [51] or the transition from Bar-
ett’s esophagus to esophageal adenocarcinoma [31] showed
o link between iron status, dietary iron intake and cancer
isk.
Several studies have evaluated data of the large
S National Health and Nutrition Examination Surveys
NHANES I and II), and found higher transferrin saturation
TSAT), partly in combination with elevated cholesterol or
igh dietary iron intake, as risk factor of developing cancer
52–57]. Conversely, the very large Swedish Apolipoprotein
ortality Risk study (AMORIS; 220,642 individuals with
ron status assessment of whom 9269 developed cancer more
han three years after the test) found a correlation between
igh total iron binding capacity (i.e. low TSAT) and cancer
isk [58]. Serum iron did not correlate with cancer risk. Anal-
sis of middle-aged people in France found a higher risk of59]. However, since serum ferritin is an acute phase protein,
t is possible that elevated serum ferritin levels observed in
uch studies are secondary to an underlying disease.
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.3.  Phlebotomy  and  blood  transfusion
Based on long-term data from national blood banks,
 nested case-control study showed no clear association
etween the risk of cancer and the number of blood donations
hat were taken as a measure of iron depletion. However, sub-
nalysis revealed a trend toward reduced risk of cancers of
he liver, lung, colon, stomach and esophagus in men with
ncreasing number of blood donations [60]. Among patients
ith peripheral arterial disease (PAD) who were randomized
o phlebotomy or no iron reduction, significantly less vis-
eral malignancies and lower mortality were observed in the
hlebotomy group [61]. The results were particularly strik-
ng because cancer incidence in treatment and control arms
egan to diverge as early as 6 months after the study started.
imilar treatment, phlebotomy combined with low-iron diet,
as been shown to reduce the risk of HCC in patients with
hronic Hepatitis C virus (HCV) infection [62].
.  Nonclinical  models  and  data
In a simplified model, carcinogenesis can be described as
 multi-step process of induction, promotion and progression
63]. Accordingly, substances involved in carcinogenesis can
e categorized as cancer inducers if they initiate the transfor-
ation of normal into cancer cells or as cancer promotors if
hey are not inherently carcinogenic but enhance the activity
f a cancer inducer. Substances that enhance tumor progres-
ion typically support the proliferation and spread of existing
ancer cells.
.1.  Can  high  iron  load  induce  tumors?
Concerns that parenteral iron might be carcinogenic origi-
ally stem from sporadic cases of sarcoma in patients treated
ith intramuscular (i.m.) iron dextran in the 1960s [23]. Ani-
al studies investigating the tumor induction potential of
ron compounds [22,23] (Table 2) used mainly subcutaneous
s.c.) or i.m. application of iron dextran or intraperitoneal
i.p.) application of ferric nitrilotriacetate (Fe-NTA) or ferric
accharate.
Initial experiments investigated sarcoma formation in
odents receiving iron dextran s.c. or i.m. over a period
f 3–17 months (total iron doses of 1583–18,200 mg/kg
odyweight) [64,65]. Depending on the dosing regime and
umulative iron dose, 55–80% of animals developed tumors.
iffering degrees of tumorigenicity were observed in other
pecies, with hamsters, rabbits, guinea pigs, dogs and squirrel
onkeys being less susceptible to iron-related cancer induc-
ion than rats or mice [64,66–68]. Varying the number of
njection sites suggested that high local iron concentration
as critical for tumor induction [69]. This particular series
f animal studies used administration routes and iron doses
hat are not comparable to i.v. iron administration in current
linical practice. Compared to relevant clinical i.v. iron doses
t
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750–3000 mg cumulative dose; i.e. 10–40 mg/kg in a 75 kg
atient) [9,12–16,70], 10- to 450-fold higher cumulative iron
oses were administered.
Lower but still high amounts of i.p. injected Fe-NTA were
equired to produce renal cell carcinoma (RCC) in rodents
71,72]. Animals received daily Fe-NTA injections over 12
eeks to achieve the observed 60–80% incidence of RCC
fter 1 year. Notably, Fe-NTA is severely nephrotoxic and
3% of animals died within 2 weeks in some experiments. In
ddition to dissociated iron, the Fe-NTA complex itself can
ndergo redox cycling under physiological conditions [73],
nd can pass the glomeruli into proximal renal tubes more
eadily than the larger and more stable iron-carbohydrate
omplexes [74]. Also noteworthy, NTA alone (albeit at high
oses) is carcinogenic [75] by mechanisms involving the
enton reaction [76] and acts as a tumor promoter [77]. There-
ore, studies involving Fe-NTA have limited relevance to the
herapeutic use of clinical iron preparations in cancer patients.
In accordance with the large iron doses used, several of
hese nonclinical studies reported iron deposits in organs and
issues. Rats receiving ferric saccharate i.p. acquired brown-
sh peritoneal serosa [68]. In iron dextran treated animals,
igmented phagocytes were localized at the site of injection,
nd hemosiderin iron deposits were detected in the liver and
idneys [64,68]. It seems likely that in these animal models,
ransfer of iron from the injection site to body iron stores
ould not keep pace with the rate and amount of adminis-
ered iron. These, high, persistent local concentrations of iron
ave been shown to induce tumor formation in some animal
odels, but not others. In contrast to i.p. administration, i.v.
dministration facilitates rapid dispersal of iron throughout
he circulation and subsequent uptake by the reticuloendothe-
ial system (RES); this administration route was not tested
ith any animal models so far reported.
.2.  Can  iron  promote  the  activity  of  known  tumor
nducers?
In a variety of animal models (Table 3), cancer was
nduced by different chemical, genetic or surgical means, and
he effect of iron on tumor promotion was investigated.
.2.1. Liver  cancer  models
Several environmental pollutants including hexachloro-
enzene (HCB), polychlorinated biphenyls (PCBs) and
iethylnitrosamine (DEN) have been shown to induce liver
ancer in animals. Due to the association of iron overload
ith HCC in humans, the possibility that iron overload might
romote the effects of these chemical carcinogens has been
nvestigated [78–81]. All the reviewed studies used massive
ingle or multiple doses of s.c. iron dextran (cumulative dose
f 600–4000 mg iron/kg body weight) in combination with
he chemical inducers. The effects of iron-loading ranged
rom increased pre-neoplastic changes [81] to development
f HCC in the long term [78].
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Table 2
Parenteral iron administration in models of cancer induction.
Tumor type, species Iron complex, route Cumulative iron dose Key outcome Ref.
Sarcoma, rat Iron dextran, i.m. 1583–4622 mg/kg 55–70% developed tumors [65]
Sarcoma, mouse, rat,
guinea pig, hamster,
rabbit
Iron dextran, s.c. or
i.m.
Mice: 5200–18200 mg/kg
Rats: 4333 mg/kg
Tumors in 76% of mice, sarcoma in 80% of
rats, low tumorigenicity in hamsters, and
none in guinea pigs or rabbits.
[64]
Sarcoma, mouse, rat,
rabbit, dog
Iron dextran, s.c. Mice: up to 4000 mg/kg
Rats: up to 833 mg/kg
Sarcomas only in mice and rats and after
multiple injections
[66]
Sarcoma, rabbit Iron dextran, i.m. 933 mg/kg Sarcoma in 33% of rabbits (follow-up study
to [64])
[68]
Sarcoma, rat Iron dextran, s.c. 2000 mg/kg Tumor incidence decreased with increased
number of injection sites
[69]
Sarcoma, squirrel monkey Iron dextran, i.m. 500 mg/kg No sarcoma or non-injection site tumors [67]
RCC, rat Fe-NTA, i.p. 360–504 mg/kg RCC in 78% of mice (43% metastases, 8%
died from nephrotox)
[71]
RCC, mouse Fe-NTA, i.p. 130–194 mg/kg RCC in 60% of male mice (53% of males
died from nephrotox), female mice less
susceptible to nephrotox and carcinogenicity
[72]
Mesothelioma, male rat Ferric saccharate and
NTA, i.p.
390 mg/kg Mesothelioma in 47% Fe-saccharate only
and 68% Fe-saccharate + NTA rats
[157]
RCC, male rat Fe-NTA, i.p. 130–182 mg/kg RCC in 53–56% of rats, tumors larger in
non-phlebotomized rats
[74]
Skin, female mouse Iron dextran, i.m. 600 mg/kg Papillomas in 50% of mice [87]
Mesothelioma, rat Ferric saccharate and
NTA, i.p.
500 mg/kg Mesothelioma in 66.7% of male but only
3.3% of female rats
[158]
i.m. intramuscular; i.p., intraperitoneal injection; NTA, nitrilotriacetic acid; RCC, renal cell carcinoma; s.c., subcutaneous.
For comparison purposes, the weight of a mouse was estimated to be 25 g, a rat 300 g, a rabbit 3 kg, and a squirrel monkey 1 kg.
Table 3
Administration of oral and parenteral iron in models of cancer promotion.
Tumor type, species Iron complex, route Cumulative iron
dose
Key outcome Ref.
HCC, mouse Iron dextran, s.c. 600 mg/kg Increased incidence of liver hyperplastic nodules and HCC [78]
HCC, mouse Iron dextran, s.c. 600 mg/kg Increased incidence of HCC [80]
HCC, female rat Iron dextran, s.c. 600 mg/kg Increased incidence and number of hepatic nodules [79]
HCC, female rat Iron dextran, s.c. 4000 mg/kg Increased number and size of GST-P expressing liver foci [81]
HCC, rat Dietary iron, oral N/A All rats on the normal diet developed hepatic adenocarcinomas [159]
Skin, female mouse Iron dextran, i.m. 560 mg/kg Higher incidence and number of tumors and earlier appearance [82]
Skin, female mouse Iron dextran, i.m. 560 mg/kg Increased frequency of papillomas and skin carcinomas [83]
Skin, female mouse Iron dextran, i.m. 600 mg/kg Higher incidence and number of tumors per mouse [86]
Skin, female mouse Iron dextran, i.m. 300–900 mg/kg Higher incidence and number of tumors and earlier appearance [160]
Skin, female mouse Iron dextran, i.m. 600 mg/kg Higher conversion rate from benign to malignant disease [85]
Skin, female mouse Iron dextran, i.m. 600 mg/kg Lower incidence of tumors in pregnant vs. virgin mice [84]
EAC, rat Iron dextran, i.p. 144 mg/kg Increased incidence of CLE, CLE with dysplasia and EAC [88]
UC and CRC, mouse Iron dextran, i.p.
Dietary iron, oral
i.p.: 216 mg/kg
dietary: N/A
Tumors in 73% of mice on oral iron vs. no tumors in i.p. group [90]
UC and CRC, mouse Dietary iron, oral N/A 88% vs. 19% CRC with iron-enriched vs. control diet [89]
CRC, mouse Dietary iron, oral N/A 42% vs. 31% tumors in high iron vs. low iron group [91]
GI tract tumors, rat Dietary iron, oral N/A Higher number of duodenal tumors in iron-deficient rats [93]
CRC, male rat Iron dextran, i.p. 75 mg/kg Similar incidence but more tumors per animal in iron group [92]
CRC, male mouse Iron dextran, s.c. No influence on intestinal tumorigenesis [136]
Breast cancer, mouse Dietary iron, oral N/A Lower tumor growth rate in low vs. normal iron group [94]
Breast cancer, female rat Dietary iron, oral N/A Moderate iron deficiency increased tumor incidence
Severe iron deficiency resulted in earlier onset
[95]
Breast cancer, female rat Dietary iron, oral N/A Low tumor incidence with low iron diet
Increased tumor incidence with excessive iron diet
[96]
Renal, Male Syrian Hamsters Dietary iron, oral N/A 70% vs. 50% with renal tumors after high vs. normal iron diet [97]
Oral, rat Dietary iron, oral N/A Similar incidence but earlier development of squamous cell
carcinomas in the iron deficient group
[100]
Lung tumors, mice Dietary iron, oral N/A Similar tumor incidence but more lung adenomas in iron
deficient mice
[101]
CLE, columnar-lined esophagus; CRC, colorectal cancer; EAC, esophageal adenocarcinoma; GI, gastrointestinal; GST-P, placental form of glutathione-S-
transferase; HCC, hepatocellular carcinoma; i.m. intramuscular; i.p., intraperitoneal; N/A, not available; s.c., subcutaneous; UC, ulcerative colitis.
For comparison purposes, the weight of a mouse was estimated to be 25 g and a rat 300 g.
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Table 4
Administration of oral or parenteral iron in models of progression of established tumors.
Tumor type, species Iron complex, route Cumulative iron dose Key outcome Ref.
Leukemia, mouse Iron dextran, i.p. 25 or 250 mg/kg More tumor cells recovered from iron-
treated animals
[102]
CRC, SW480 and Caco-2 cells Ferrous sulfate, in vitro N/A Significant increase in cellular proliferation [103]
EAC, OE33 and SEG-1 cells Ferrous sulfate, in vitro N/A Less TfR1 and DMT1 mRNA, more
H-ferritin protein
[104]
Hepatoma, colon AC,
mammary AC, mouse
Dietary iron, oral N/A Tumors grew slower in the low iron group [105]
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or comparison purposes, the weight of a mouse was estimated to be 25 g.
.2.2.  Skin  cancer  models
Animal models of skin cancer typically perform a
wo-step process involving topically applied tumor induc-
rs followed by tumor promoters. Inducers, such as 7,
2-dimethylbenz(a)anthracene (DMBA), cause genetic alter-
tions, while promoters such as topical peroxide, TPA
12-O-tetradecanoylphorbol-13-acetate), BPO (benzoylper-
xide) or croton oil induce inflammation and oxidative stress
o favor tumor formation. The effect of iron overload as a
umor promoter in animals which have received tumor ini-
iators only [82] or both initiators and promoters [83–86]
as been studied. In all cases, except in pregnant female
ice [84], severe iron overload promoted tumor formation.
xperiments typically used high cumulative doses of i.m. iron
extran (300–900 mg iron/kg body weight). The absence of
umors in iron-treated animals not receiving tumor initiators
emonstrates that parenteral iron overload can promote but
oes not induce skin cancer in these models [87].
.2.3. GI  tract
In rats with surgically induced esophageal adenocarci-
oma (EAC), tumor formation was significantly promoted in
nimals receiving only moderately excessive doses of i.p. iron
extran [88]. Similar to observations in other tumor induction
odels, no tumors formed with i.p. iron alone.
In a mouse dextran sulfate sodium (DSS) model of
lcerative colitis (UC), increased dietary iron intake was
ccompanied by increased tumor incidence [89]. However,
urther experiments showed that this phenomenon was spe-
ific for dietary iron, while parenteral iron did not promote
umor formation in the same model [90]. In a second
odel, using IL-2 knockout mice that develop spontaneous
nflammation, parenteral iron replenished splenic iron and
ignificantly reduced inflammation in the colon without
ncreasing hyperplastic lesions [90].
In a model of CRC using the colonotropic carcinogen,
zoxymethane (AOM), tumor incidence increased in AOM-
reated mice placed on a high iron diet compared to those
laced on a low iron diet; dietary iron alone did not initiate
umors [91]. In another CRC model using the carcinogenic
nducer dimethylhydrazine (DMH), parenteral iron increased
he tumor burden without significantly increasing tumor inci-
ence [92]. Authors of both studies concluded that in these
3
g
mC, esophageal adenocarcinoma; TfR, transferrin receptor.
arcinogen-induced CRC models, iron exerted its effects as
 tumor promoter but not as a tumor inducer. In contrast,
n another study of DMH-induced CRC, duodenal but not
olonic tumors were more frequent in iron deficient than iron
eplete rats [93], suggesting that tumor promotion in these
RC models varies with the type of chemical inducer and
ron supplementation.
.2.4.  Breast  and  estrogen-related  cancers
In animal models of breast cancer [94–96], a trend-wise
orrelation of tumor incidence and/or tumor growth with
ietary iron uptake was observed. However, in one study,
limination of confounding factors such as anemia and low
ody weight abolished differences between animals on low
nd normal iron diet [96]. In another study, a moderately iron
eficient diet increased both tumor incidence and tumor bur-
en, whereas severe iron deficiency resulted in rapid onset
f tumor formation but ultimately lower tumor incidence and
urden [95]. In this particular study, increased tumor develop-
ent in iron deficient rats was attributed to decreased natural
iller (NK) cell cytotoxicity.
In male Syrian hamsters that develop renal cancer follow-
ng 17-estradiol treatment, tumor incidence was increased
n animals on high versus low iron diet [97]. The mech-
nism of estrogen-induced tumor formation may involve
edox cycling of catecholestrogen metabolites such as 4-
ydroxyestradiol and superoxide radical formation. In the
resence of Fe2+, conversion of superoxide to H2O2 by
OD could lead to hydroxyl radicals via the Fenton reac-
ion. Interestingly, expression of enzymes required to produce
atecholestrogen metabolites in the organs of rodents corre-
ate with their susceptibility to estrogen-induced tumors [98].
dditionally, there may be a synergistic effect between 17-
stradiol and dietary iron on iron homeostasis, since animals
reated with 17-estradiol alone accumulated iron in the liver
nd kidneys [97]. Accordingly, an estrogen-responsive region
n the transferrin promoter that upregulates transferrin expres-
ion in a 17-estradiol-incubated breast cancer cell line has
een identified [99]..2.5.  Other  cancers
Two additional models of chemically induced carcino-
enesis, one a rat model of oral cancer and the other a mouse
odel of lung cancer, support the notion that iron deficiency
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an increase tumor incidence or promote tumor development
100,101]. In the second study, no increase in lung adenoma
ncidence was found in mice with elevated systemic iron
evels due to diets containing up to 5000 ppm iron.
.3.  Can  iron  inﬂuence  the  progression  of  established
umors?
In a mouse model of leukemia, mice received an i.p. injec-
ion of 25 or 250 mg iron/kg body weight (iron dextran) 6 h
rior to i.p. injection of tumor cells. In this study, leukemia
ell proliferation was greater in iron-treated animals than
n controls without iron treatment [102]. The timing and
natomical proximity of iron and tumor cell injections in this
odel suggests a direct effect of iron on tumor proliferation,
s observed with in vitro studies [103,104] (Table 4).
In a model using three different tumorigenic cell lines
ransplanted into severely iron deficient mice, tumor sizes
ere smaller than in iron replete controls [105]. However,
n these anemic mice, negative effects of iron deficiency on
utritional status may have also contributed to reduced tumor
rowth.
.4.  The  role  of  iron  chelators  in  tumor  promotion
odels
An alternative approach to study the role of iron in cell pro-
iferation is to reduce available iron by systemically applied
ron chelators (e.g. deferoxamine [DFO]) [106,107] that
nhance renal iron excretion. Furthermore, iron chelators are
nvestigated as potential new anti-cancer therapies that exert
arious modes of action beyond sequestration of iron from
apidly proliferating cancer cells [108,24]. Iron chelators
ffect expression of diverse genes, including those involved
n cell cycle control such as p53, cyclins, cyclin dependent
inases, GADD45 and WAF1, but also the tumor suppres-
or gene Ndrg1 as well as p38 MAPK, ERK and HIF-1
109,110].
DFO was initially found to reduce the size of rat mam-
ary adenocarcinomas and human HCC tumor transplants
n athymic nude mice [111,112]. DFO also reduced the num-
er of preneoplastic hepatic lesions in rats prone to severe
iver fibrosis and HCC due to excessive lipid peroxidation
fter a choline- and l-amino acid-defined diet [113]. How-
ver, iron chelators had no effect on xenograft models of
uman neuroblastoma, cervical carcinoma or AIDS-related
aposi’s sarcoma, despite varying effects on reduction of
ystemic iron [114–116]. In the Kaposi’s sarcoma model,
FO actually enhanced tumor growth, which could be attenu-
ted by administration of iron-saturated DFO. Possibly, DFO
romoted proliferation via anti-apoptotic mechanisms since
he apoptotic index of tumor cells in DFO-treated animals
as significantly decreased. Conversely, DFO or low iron
iet increased in situ apoptosis in the rat 1376NF mammary
denocarcinaoma model [117].
m
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A panel of different iron chelators including di-2-pyridyl-
erived chelators such as Dp44mT have been developed that
nduce tumor cell apoptosis in a range of xenograft models
118,119]. Pyridoxal isonicotinoyl hydrazone (PIH) deriva-
ives, containing di-pyridyl ketone isonicotinoyl hydrazone
PKIH) and its analogs, showed high antiproliferative activity
ith more specificity toward neoplastic SK-N-MC neuroep-
thelia cells than untransformed MRC-5 fibroblasts [120].
otably, iron-loaded PKIH analogs demonstrated the same
nti-proliferative activity as the iron-free chelator. It has been
hown that PKIH increases the generation of ROS through
edox cycling of the iron complex [121].
Recently published experiments with eltrombopag, a
mall-molecule thrombopoietin receptor antagonist and
etal chelator, showed a dose-dependent reduction of free
ntracellular iron and cell division rates, a G(1) cell cycle
rrest and increased differentiation in human and murine
eukemia cells (HL60, U937, URE) [122]. Furthermore,
ltrombopag prolonged survival in murine leukemia trans-
lantation models. Preloading cells with ferric ammonium
itrate (500 g/mL, 24 h) to increase intracellular iron
brogated the in vitro anti-proliferative and differentiation-
nducing effects. Notably, cells with increased iron but no
ltrombopag showed no increase in proliferation rate, differ-
ntiation and morphological changes compared to untreated
ontrols.
.  Involvement  of  iron  in  mechanisms  of
arcinogenesis
Mechanisms how iron may contribute to tumor induction
r progression in clinical and nonclinical models as outlined
bove have been reviewed extensively [1,22–24]. Such mech-
nisms include oxidative DNA damage by iron-catalyzed free
adical production, alterations in gene expression consistent
ith increased iron requirements in proliferating cells (Fig. 1)
s well as decreased immune surveillance against cancer.
.1.  Oxidative  damage  to  cellular  constituents
Under conditions of iron overload, levels of non-
ransferrin bound iron (NTBI) and intracellular labile iron
ncrease, and can catalyze the production of reactive oxy-
en species (ROS) which may lead to organ dysfunction
123,124]. An increase of DNA breaks was found in leuko-
ytes obtained from rats chronically fed a diet containing
xcess FeSO4 as well as after incubation of human leuko-
ytes, primary colonocytes or tumor cell lines with Fe-NTA
125–127]. Interestingly, a comparison of Fe-NTA with
rganic iron (heme and hemin) and inorganic iron (FeSO4),
howed that organic, rather than inorganic iron compounds
ay promote carcinogenic events [128]. In non-neoplastic
at liver epithelial cells that were previously initiated
ith N-methyl-N′-nitro-N-nitrosoguanidine (MNNG), ferric
mmonium citrate enhanced neoplastic colony formation in
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 dose-dependent manner, but cell proliferation was substan-
ially inhibited at the iron concentrations used [129].
.2.  Altered  gene  expression  patterns  of  proteins
nvolved  in  iron  homeostasis  and  proliferation
In general, genes encoding proteins that increase
ntracellular iron (TRFC [transferrin receptor], SLC11A2
divalent metal transporter 1, DMT1] and HAMP [hep-
idin]) are upregulated in tumor cells, whilst those decreasing
ron levels (SLC40A1 [ferroportin]) are downregulated
103,104,24,130,131]. Among breast cancer patients, lower
erroportin levels in tissue biopsies correlated with severity
f histological grade, molecular subtype and worse long-
erm prognosis [131]. In two mouse cancer models, tumor
rowth rates and formation of metastases could be reduced
y increasing ferroportin and decreasing TfR expression lev-
ls in transplanted tumor cells [130,131]. In line with these
bservations, the induction of the tumor suppressor p53 in
ung and colorectal cancer cell lines increased ferritin and
ecreased TfR protein levels [132], and p53 may induce cell
ycle arrest via restricted availability of intracellular iron to
ron-dependent enzymes (cyclin, cyclin-dependent kinases,
ibonucleotide reductase) [133]. In addition, hepcidin levels
ay be influenced via a p53 response element in the HAMP
romoter [134].
Involvement of the Wnt signaling pathway has been pro-
osed for iron-mediated proliferation of colorectal cancer
CRC) cell lines [135]. In this model, iron loading enhanced
nt signaling activity only in cells mutant for Adeno-
atous Polyposis Coli Protein (APC) or cells expressing
onstitutively active -catenin. However, in mice carrying
n Apc-germline mutation that mimics familial adenomatous
olyposis, a hereditary form of CRC [136], administration of
igh iron doses (2000 mg/kg body weight s.c. on two con-
ecutive days followed by once monthly), did not promote
ntestinal tumorigenesis.
In lymphoma cell lines with translocated copies of c-myc,
ron can inhibit proliferation via free radical-mediated DNA
amage and downregulation of c-myc expression [137,138].
.3.  Iron  and  immune  surveillance  of  cancer
Iron can modulate activity of the innate and adap-
ive immune system, including NK cells, monocytes,
acrophages and lymphocytes. As noted earlier, iron seques-
ration (principally by monocytes and macrophages of the
eticuloendothelial system) has been argued to represent a
echanism by which the body withholds iron from invad-
ng pathogens and virus-infected cells [133]. Consistent
ith this idea, low iron status has been associated with
nhanced immunoprotection against certain infections such
s malaria and tuberculosis [139,140]. However, innate and
ell-mediated immunity can also be impaired by iron defi-
iency [141]. For example, in iron-deficient but otherwise
ealthy elderly women, T-cell proliferation in response to
l
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itogenic stimuli was reduced compared to the response in
ron-replete women [142]. Similarly, rats fed a moderately
ron-deficient diet and challenged with the carcinogen DMBA
ad a higher tumor burden and reduced NK cell activity com-
ared to rats fed a normal iron diet [95]. In T-lymphocytes,
ron reduces activation of the pro-apoptotic/anti-proliferative
nterferon- (IFN-)/STAT1 pathway and favors the dif-
erentiation of T helper 1 (TH1) cells, which could favor
ytotoxic anti-microbial and anti-tumor responses. However,
n a different context, iron supplementation was also shown
o protect malignant T cells from IFN-  induced apoptosis
n vitro, while in vivo, iron chelation plus IFN-  treatment
nhibited malignant T cell growth in a severe combined
mmunodeficient (SCID) mouse model [143]. Furthermore,
n macrophages, high intracellular iron concentration can
nhibit the IFN--stimulated release of oxygen radicals and
itric oxide (NO) [144], which are key effector pathways in
nnate immunity. In monocytes, iron reduces surface expres-
ion of cell adhesion molecules such as intracellular cell
dhesion molecule 1 (ICAM-1) and human leukocyte anti-
en (HLA)-DR, which are important in leukocyte migration,
-cell mediated killing and other T- and B-cell responses con-
ributing to adaptive immunity [145]. Hence, the interplay
f iron metabolism and regulation of immune responses is
omplex and context dependent [145].
. Discussion
Intravenous iron supplementation has proven its efficacy
nd tolerability, and is recommended in guidelines on the
anagement of chemotherapy-induced anemia [11,17]; yet,
ome uncertainty remains about long-term effects in can-
er patients since long-term follow-up data have not been
ecorded. Therefore, human epidemiological data or non-
linical studies have to be evaluated for evidence or hints
n a potential role of iron in carcinogenesis. However, these
tudies often do not reflect the clinical setting in oncology
atients and their results are thus inconclusive. Overall, the
ata suggest that chronic iron overload (e.g. in hereditary
emochromatosis; TSAT >45%, serum ferritin >1000 ng/mL
uggesting cirrhosis) increases the risk of cancer. However,
ron deficiency can also negatively affect clinical outcomes
nd immune surveillance. Thus, maintenance or achievement
f a normal iron status with appropriate use of i.v. iron at a
ather wide TSAT target range of 20–50% [18] seems to be
easonable in cancer patients receiving chemotherapy.
.1.  Human  data
While iron overload in hereditary hemochromatosis
caused by HFE  mutations) is associated with higher risk of
iver cancer, the influence of HFE  mutations on risk of other
ancers remains under debate. Epidemiological studies on
ther risk factors for cancer showed links with high dietary
ron intake or iron status, particularly for CRC. It appears
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hat the intraluminal milieu can trigger oxidative/genotoxic
hanges in gut epithelial cells that may lead to GI tract can-
ers. Importantly, cells exposed to the gut lumen are not
ubject to the same control of iron metabolism as reticuloen-
othelial cells.
In patients with multiple myeloma, deviation from nor-
al TSAT (<20% or >45%) was associated with reduced
rogression-free and overall survival as well as markers
f impaired organ function (i.e. increased prohormone of
rain natriuretic peptide [proBNP], and reduced estimated
lomerular filtration rate [eGFR]) [146]. However, it can-
ot be clearly distinguished whether the abnormal TSAT was
he reason for impaired survival or caused by already more
dvanced malignancy. Notably, 47% of multiple myeloma
atients with available iron status were either iron-deficient
32%) or had iron overload (15%) which may have resulted
rom the high transfusion frequency in this subgroup.
Intentionally reduced iron status (phlebotomy) in PAD
atients showed a striking reduction in cancer risk already
fter 6 months on the trial; yet, confirmatory studies are warr-
nted since the study participants’ demographics may have
onfounded the results [147].
.2.  Nonclinical  data
Data on the role of iron as a tumor inducer derive mainly
rom nonclinical studies involving either iron dextran (i.m.
r s.c.) or Fe-NTA (i.p.). The carcinogenicity of the highly
edox active Fe-NTA precludes meaningful extrapolation of
onclinical data with this agent to clinical studies employ-
ng non-genotoxic iron-carbohydrate formulations approved
or clinical use. Numerous animal studies, particularly in
odents, have shown sarcoma development after s.c. or i.m.
elivery of iron dextran at cumulative doses at least 1–2 orders
f magnitude higher than those employed in the clinical set-
ing. As noted previously, tumor induction in this setting is
ikely related to persistent and localized iron overload.
As with the population studies [38], cancer models suggest
hat excessive iron within the gut luminal environment may
romote GI tract tumors. However, considerable differences
n experimental outcomes may reflect different susceptibility
f various GI tract regions to the tumor promoting effects of
ither iron deficiency or iron overload. Some studies provided
vidence for enhanced growth rate of implanted [105] or
pontaneous tumors [94] and increased incidence of estrogen-
nduced tumors [97] in animals receiving high iron diets.
onversely, no evidence was found for a role of dietary iron
n the promotion of oral and lung cancers [94–96,100,101],
nd one study demonstrated increased tumor incidence in
ron deficient animals [95].
Only one chemical carcinogen model and one tumor
mplantation model used iron doses similar to those indi-
ated for parenteral iron replacement therapy [92,102]. Both
tudies involved i.p. administration of iron dextran, close
o or directly at the site of subsequent tumor formation. In
hese instances, the high MW iron-dextran complexes may
l
i
2logy/Hematology 89 (2014) 1–15
ave been retained in the peritoneal cavity and exposed cells
ining the cavity to excessive iron levels. In the clinical set-
ing of i.v. administration, a comparable situation is unlikely
ince iron is rapidly targeted to the RES [148]. To the best of
ur knowledge, no nonclinical cancer model using the clini-
ally relevant i.v. administration route has been published to
ate.
In vitro studies investigating the genotoxicity and cyto-
oxicity of iron (mainly as ferrous sulfate, hemoglobin and
emin rather than clinically used parenteral iron prepara-
ions) should be interpreted within the context of the limited
n vivo evidence for potential tumorigenic activity. In vitro
tudies may present several possible mechanisms by which
ron could induce cancer, including oxidative DNA dam-
ge; however, the contribution of these mechanisms can
nly be estimated when the data are taken in conjunction
ith in vivo data from animal studies and human epidemiol-
gy.
.3.  Iron  in  the  clinical  setting
In oncology patients, i.v. iron therapy is indicated for
he restoration of normal iron status and correction of ane-
ia. International anemia treatment guidelines recommend
dministration of i.v. iron if functional iron deficiency is
resent, and repletion of iron stores if absolute iron defi-
iency is the underlying cause of anemia [18]. Clearance of
.v. iron complexes from the circulation, uptake by the RES,
ppropriate iron deposition in physiological iron stores and
he generation of ROS are influenced by the physicochemical
roperties of iron complexes including their reduction poten-
ial, the strength of iron binding and the molecular weight
f the complex [124,149,150]. Inefficient delivery of iron to
hysiological iron stores and excessive transferrin saturation
fter i.v. or oral iron supplementation may result in iron depo-
ition in liver cells where it is associated with histopathology
n animals and in mesenchymal cells [151–155].
.  Conclusions
Human data, mainly based on cases after i.m. injection
f iron dextran and populations with chronic iron overload,
uggest a correlation between chronically increased iron lev-
ls and increased cancer risk. Animal models, mainly based
n non-intravenous administration of extremely high cumu-
ative iron doses in iron-replete recipients, suggest that iron
verload can promote tumor growth. Overall, data from epi-
emiological and nonclinical studies are often conflicting and
xtrapolation to the clinical setting aiming for normalization
f hemoglobin (around 12 g/dL) is difficult. In the absence
f long-term pharmacovigilance studies, iron treatment to
revent or manage chemotherapy-induced anemia should be
imited to the time of cytotoxic anti-tumor treatment and
ron status should be closely monitored (target TSAT range
0–50%).
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